Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladiratuzumab vedotin alone and with pembrolizumab in advanced solid tumors
NCT04032704Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Oct 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ladiratuzumab vedotin in small cell lung cancer (SCLC), squamous cell carcinoma of the lung (SCCL), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Seagen Inc.. Started Oct 2019; status: terminated.
02
Drugs
ladiratuzumab vedotin
03
Conditions
small cell lung cancer (SCLC)squamous cell carcinoma of the lung (SCCL)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04032704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032704.